These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
708 related articles for article (PubMed ID: 33129371)
1. Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7. Amatya C; Pegues MA; Lam N; Vanasse D; Geldres C; Choi S; Hewitt SM; Feldman SA; Kochenderfer JN Mol Ther; 2021 Feb; 29(2):702-717. PubMed ID: 33129371 [TBL] [Abstract][Full Text] [Related]
2. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells. Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735 [TBL] [Abstract][Full Text] [Related]
3. SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7 Gogishvili T; Danhof S; Prommersberger S; Rydzek J; Schreder M; Brede C; Einsele H; Hudecek M Blood; 2017 Dec; 130(26):2838-2847. PubMed ID: 29089311 [TBL] [Abstract][Full Text] [Related]
4. Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization. Hanssens H; Meeus F; De Vlaeminck Y; Lecocq Q; Puttemans J; Debie P; De Groof TWM; Goyvaerts C; De Veirman K; Breckpot K; Devoogdt N Front Immunol; 2024; 15():1389018. PubMed ID: 38720898 [TBL] [Abstract][Full Text] [Related]
5. Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-Recognition Domains. Choi S; Pegues MA; Lam N; Geldres C; Vanasse D; Kochenderfer JN Hum Gene Ther; 2021 Jul; 32(13-14):730-743. PubMed ID: 33287637 [TBL] [Abstract][Full Text] [Related]
6. Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells. Starr R; Aguilar B; Gumber D; Maker M; Huard S; Wang D; Chang WC; Brito A; Chiu V; Ostberg JR; Badie B; Forman SJ; Alizadeh D; Wang LD; Brown CE Cancer Res Commun; 2023 Jan; 3(1):66-79. PubMed ID: 36968221 [TBL] [Abstract][Full Text] [Related]
7. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains. Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568 [TBL] [Abstract][Full Text] [Related]
8. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia. Cheng Z; Wei R; Ma Q; Shi L; He F; Shi Z; Jin T; Xie R; Wei B; Chen J; Fang H; Han X; Rohrs JA; Bryson P; Liu Y; Li QJ; Zhu B; Wang P Mol Ther; 2018 Apr; 26(4):976-985. PubMed ID: 29503204 [TBL] [Abstract][Full Text] [Related]
9. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells. Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319 [TBL] [Abstract][Full Text] [Related]
10. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641 [No Abstract] [Full Text] [Related]
11. Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma. Korst CLBM; O'Neill C; Bruins WSC; Cosovic M; Twickler I; Verkleij CPM; Le Clerre D; Themeli M; Chion-Sotinel I; Zweegman S; Galetto R; Mutis T; van de Donk NWCJ J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39060023 [TBL] [Abstract][Full Text] [Related]
12. Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. Wang X; Walter M; Urak R; Weng L; Huynh C; Lim L; Wong CW; Chang WC; Thomas SH; Sanchez JF; Yang L; Brown CE; Pichiorri F; Htut M; Krishnan AY; Forman SJ Clin Cancer Res; 2018 Jan; 24(1):106-119. PubMed ID: 29061640 [No Abstract] [Full Text] [Related]
13. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265 [TBL] [Abstract][Full Text] [Related]
14. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Mamonkin M; Mukherjee M; Srinivasan M; Sharma S; Gomes-Silva D; Mo F; Krenciute G; Orange JS; Brenner MK Cancer Immunol Res; 2018 Jan; 6(1):47-58. PubMed ID: 29079655 [TBL] [Abstract][Full Text] [Related]
15. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Salter AI; Ivey RG; Kennedy JJ; Voillet V; Rajan A; Alderman EJ; Voytovich UJ; Lin C; Sommermeyer D; Liu L; Whiteaker JR; Gottardo R; Paulovich AG; Riddell SR Sci Signal; 2018 Aug; 11(544):. PubMed ID: 30131370 [TBL] [Abstract][Full Text] [Related]
16. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma. Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195 [TBL] [Abstract][Full Text] [Related]
17. T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication. Ng YY; Tay JCK; Li Z; Wang J; Zhu J; Wang S Mol Ther; 2021 Jan; 29(1):75-85. PubMed ID: 32956627 [TBL] [Abstract][Full Text] [Related]
18. Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity. Li W; Guo L; Rathi P; Marinova E; Gao X; Wu MF; Liu H; Dotti G; Gottschalk S; Metelitsa LS; Heczey A Hum Gene Ther; 2017 May; 28(5):437-448. PubMed ID: 27530312 [TBL] [Abstract][Full Text] [Related]
19. TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors. Nishimura CD; Corrigan D; Zheng XY; Galbo PM; Wang S; Liu Y; Wei Y; Suo L; Cui W; Mercado N; Zheng D; Zhang CC; Zang X Sci Adv; 2024 May; 10(19):eadk1857. PubMed ID: 38718110 [TBL] [Abstract][Full Text] [Related]